Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL27491959 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11580251 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27174195 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL5571060 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27882921 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL26630598 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL5617381 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4818293 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL633793 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11857836 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120189618-A | Ureteral stent and manufacturing method thereof | 湖南半陀医疗科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119708547-A | Metal-coated organic silicon resin microsphere and preparation method and application thereof | 江苏涌新材料科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119529328-A | Metal-coated organosilicon elastomer microsphere, and preparation method and application thereof | 江苏涌新材料科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20250000865-A1 | COMPOUND FOR REDUCING URIC ACID LEVELS | NEWSOARA BIOPHARMA CO., LTD. (CN) | 2025-01-02 | — | — | US | claimed |
| CN-118268550-A | Method for preparing high sphericity nano nickel powder | 元颉新材料科技(浙江)有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118079003-A | Phosphodiesterase type 5 inhibitors for lowering uric acid levels and uses thereof | 海南大学 | 2024-05-28 | — | — | CN | claimed |
| CN-114530598-B | Nitrogen-oxygen-sulfur doped carbon negative electrode material and preparation method and application thereof | 广东工业大学 | 2024-05-07 | — | — | CN | claimed |
| US-20240024385-A1 | PROBIOTIC STRAIN FOR REDUCING SERUM URIC ACID, COMPOSITION AND USE THEREOF | Ningbo Beiyijia Biotechnology Co., Ltd. (CN) | 2024-01-25 | — | — | US | claimed |
| CN-115448289-B | Oxygen-fluorine co-doped hard carbon anode material and preparation method and application thereof | 广东工业大学 | 2023-12-01 | — | — | CN | claimed |
| CN-116924902-A | Preparation method of sodium potassium hydrogen citrate particles | 石家庄杏林锐步医药科技股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-102429887-B | Sodium-potassium citrate chewing tablet and preparation method thereof | UNIV SOUTHWEST | 2013-01-02 | — | — | CN | claimed |
| CN-102699341-A | Wet-chemical preparation method for silver micro/nanowires | XIONGHUI CAI | 2012-10-03 | — | — | CN | claimed |
| CN-102429887-A | Potassium sodium citrate chewable tablet and preparation method thereof | UNIV SOUTHWEST | 2012-05-02 | — | — | CN | claimed |
| CN-101831668-B | Clean wet-method solid-liquid two-phase electroreduction lead recovery method | UNIV BEIJING CHEMICAL | 2012-02-22 | — | — | CN | claimed |
| CN-101831668-A | Clean wet-method solid-liquid two-phase electroreduction lead recovery method | UNIV BEIJING CHEMICAL | 2010-09-15 | — | — | CN | claimed |
| CN-101480387-A | Aceclofenac pharmaceutical composition | WENJU WANG (CN) | 2009-07-15 | — | — | CN | claimed |
| US-20040007469-A1 | Forming three-dimensional multilayer structures by electroplating, ammonium citrate is included to improve anode dissolving, prevent deposits defect and short circuits, use low voltage; copper deposits has ductility, noncracking | MEMGEN CORPORATION | 2004-01-15 | — | — | US | claimed |
| US-5849268-A | Oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-15 | — | — | US | claimed |
| US-5620679-A | Oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1997-04-15 | — | — | US | claimed |
| WO-1995031174-A1 | ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000865-A1 | COMPOUND FOR REDUCING URIC ACID LEVELS | PDE4A, PDE4B, PDE12 | MEN1 2761/4885ALDH1A1 287/4885HMGCR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.